Odyssey Corporation operates as a diversified financial services firm primarily engaged in trading equity securities, managing investment portfolios, and providing business consultancy services.
The company lacks a durable competitive advantage, as evidenced by its low average ROCE of 2.2% and ROE of 1.2%. Its primary activities—trading shares and providing unsecured loans—are commodity-like services with no evidence of brand power, switching costs, or scale advantages that protect margins.
Capital has been deployed into low-return activities, including significant interest-free unsecured loans to subsidiaries and related parties. Recent actions include issuing warrants and preferential shares to promoters while maintaining a negative cash conversion ratio, suggesting poor reinvestment discipline.
The investment collapsed as the reported profits never materialized into cash, eventually leading to a liquidity crisis. The massive pile of interest-free loans to related parties, which lacked repayment schedules, was eventually written off as unrecoverable, revealing the balance sheet as a hollow shell. As the company failed to finalize its NBFC license surrender, regulatory scrutiny intensified, and the constant turnover of key personnel left the firm rudderless during the ensuing legal and financial fallout.
RichFakir rates Odyssey Corporation Ltd's business quality as poor — 5/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, Odyssey Corporation Ltd is trading far above our estimate of fair value (expensive on our lens); we rate its price expensive. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Odyssey Corporation Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
RichFakir's educational estimate of Odyssey Corporation Ltd's fair value is about ₹1 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →